Vascular cognitive impairment (VCI) is difficult to recognize because it masquerades as other conditions, lacks clear diagnostic boundaries, and operates differently in the brain than the dementia most people expect. When a 67-year-old woman has a stroke and begins moving slowly through her thoughts, struggling with attention and planning but maintaining her ability to recall what happened at lunch, clinicians often miss the cognitive impairment entirely—attributing her sluggish thinking to depression or normal aging rather than vascular brain damage. The challenge isn’t that VCI is rare; it’s that the condition sits at the intersection of vascular disease and neurodegeneration, making it nearly invisible to diagnostic frameworks that evolved to detect Alzheimer’s disease.
Recent revisions to diagnostic criteria reflect decades of confusion. In 2024 and 2025, international experts updated the VasCog-2-WSO diagnostic criteria for the first time since 2014, acknowledging that prior inconsistency in recognizing VCI had left countless patients without diagnosis. These revisions expanded the definition from memory loss alone to include six cognitive domains—attention and processing speed, executive function, learning and memory, language, perceptual-motor function, and social cognition. This shift means that vascular impairment affecting decision-making or mental speed now counts as VCI, even if memory appears intact.
Table of Contents
- What Makes Vascular Brain Changes So Difficult to Identify?
- Why VCI Symptoms Mirror Other Diagnoses—And Lead to Missed Diagnosis
- The Underdiagnosis Crisis—How Many Cases Go Unrecognized?
- Why the First Year After Stroke Is a Critical Window—And Why It Often Fails to Detect VCI
- How Clinician Confidence and Awareness Gaps Prevent Early Detection
- The Overlap Problem—How Mixed Pathology Complicates Every Case
- Emerging Detection Methods—What’s Beginning to Close the Recognition Gap
What Makes Vascular Brain Changes So Difficult to Identify?
The core recognition problem lies in mixed pathology. Approximately 80% of dementia patients have both vascular and Alzheimer’s-related brain changes at autopsy, yet clinicians rarely detect this combination during life. When a patient is scanned and shows white matter damage from strokes alongside amyloid accumulation typical of Alzheimer’s, the question of which condition drives their cognitive decline becomes impossible to answer without specialized testing—and even specialized testing often leaves uncertainty. A 72-year-old man with mild cognitive impairment might have brain imaging showing both vascular lesions and evidence of amyloid, leaving his neurologist unable to confidently tell him whether he has VCI, Alzheimer’s, or both. The criteria revision from 2014 to 2024 occurred because prior inconsistency in defining VCI created a diagnostic vacuum. When different researchers and clinicians used different definitions, patients referred to different medical centers received conflicting assessments.
One center might diagnose “probable vascular dementia” while another identified “possible Alzheimer’s disease with vascular components”—not because of genuine clinical disagreement, but because they were applying different standards. This inconsistency meant that epidemiological data on VCI prevalence varied wildly, specialist referrals were unpredictable, and patients themselves often received unclear explanations of their diagnosis. The expansion of cognitive domains now assessed reflects another recognition barrier: VCI often doesn’t announce itself as memory loss. Early vascular impairment typically affects executive function—the ability to plan, organize, and process information quickly—before it noticeably impairs memory. A person with early VCI may function well in a quiet neuropsychology office but struggle with complex decision-making or lose track of multistep tasks. This pattern differs sharply from Alzheimer’s disease, where early memory impairment is the signature symptom, making the neuropsychological profiles visibly different once tested. However, most primary care clinicians do not routinely conduct formal cognitive testing, so this distinction remains invisible.
Why VCI Symptoms Mirror Other Diagnoses—And Lead to Missed Diagnosis
Symptom overlap between VCI and Alzheimer’s disease is profound and often unrecognized by patients and their families. Because most people with Alzheimer’s disease have blood vessel damage contributing to their cognitive decline, and most people with VCI have Alzheimer’s-related brain changes, the two conditions exist on a continuum rather than as distinct categories. A 70-year-old woman presenting with slowed thinking, difficulty with organization, and word-finding difficulty might receive a diagnosis of “mild cognitive impairment, type unspecified” from one clinician and “possible Alzheimer’s disease” from another—despite the same presenting symptoms. The neuropsychological signature difference between VCI and Alzheimer’s exists but requires specialized testing to detect. In VCI, processing speed and executive function decline markedly while memory remains relatively preserved in early stages. In Alzheimer’s, memory impairment predominates, often accompanied by problems in language and spatial orientation. A person with VCI might score very low on timed executive function tests but perform normally on delayed-recall memory tasks.
A person with Alzheimer’s shows the opposite pattern. However, this difference is only observable through formal neuropsychological assessment—the kind conducted by specialists, not during routine office visits. Many patients never receive this level of testing, so the distinction goes unnoticed. A significant limitation of traditional diagnostic tools adds another layer of difficulty. The Hachinski Ischemic Scale, widely used to identify vascular contributions to dementia, requires that a dementia diagnosis already be established. This means the tool cannot identify VCI in earlier stages—those crucial years when cognitive impairment is mild or when the person’s symptoms haven’t yet crossed into the dementia range. A 65-year-old man with clear vascular risk factors, brain imaging showing multiple small strokes, and objective cognitive impairment on testing might not meet dementia criteria yet, meaning the Hachinski Scale cannot be applied to guide his diagnosis. By the time his cognitive decline worsens enough to meet dementia thresholds, the opportunity for early intervention has passed.
The Underdiagnosis Crisis—How Many Cases Go Unrecognized?
Vascular cognitive impairment is underreported, under-assessed, and under-treated across healthcare systems, despite affecting 15 to 30 percent of all dementia patients globally. The reasons for underdiagnosis involve stigma, logistical barriers, lack of awareness among both clinicians and the public, and therapeutic nihilism—the belief that because there’s no cure, diagnosis doesn’t matter. A patient presenting to a busy primary care office with complaints of slower thinking after a stroke receives a prescription for an antidepressant and is told to “expect some cognitive changes with age.” No formal assessment occurs, no specialist referral is made, and the VCI remains unrecognized and untreated. Post-stroke, the statistics reveal how profound the recognition gap becomes.
Studies show that at one year after stroke, 18 percent of patients have post-stroke dementia, or 20 percent when including those with dementia present before the stroke. Yet prevalence estimates vary dramatically by stroke type, assessment timing, and diagnostic criteria used—ranging from 8.2 to 78.7 percent in research studies. This wide variation suggests that many cases are missed in clinical practice. In China, where epidemiological data is more precise, vascular-related mild cognitive impairment accounts for 42 percent of all mild cognitive impairment cases, yet remains clinically underrecognized. If two in five people with mild cognitive impairment have a vascular etiology, but clinicians only diagnose Alzheimer’s-related MCI, half the population goes misidentified.
Why the First Year After Stroke Is a Critical Window—And Why It Often Fails to Detect VCI
Cognitive impairment appears within the first year after stroke in up to 60 percent of cases, yet systematic screening during this period remains inconsistent. Barriers exist at every level: clinicians lack standardized protocols for cognitive assessment post-stroke, rehabilitation centers don’t routinely include neuropsychological testing, and primary care follow-up visits focus on cardiovascular outcomes and medication adherence rather than cognition. A patient discharged from the hospital three days after an ischemic stroke receives instructions on blood pressure management and antiplatelet therapy but no cognitive screening. Six months later, when the same patient complains to family that he’s having trouble organizing his finances or following conversations, he’s often told “that’s normal recovery” or “it will improve with time.” The timing of testing matters critically.
Post-stroke cognitive impairment can improve spontaneously in some cases during the first three months, remain stable in others, and progress in still others. Without baseline cognitive assessment at discharge and repeated testing at defined intervals, clinicians cannot distinguish between expected recovery and true cognitive decline. A 74-year-old woman with a left-hemisphere stroke who appears to recover well from her language symptoms might have significant impairment in executive function and processing speed that develops or emerges once the acute recovery phase ends. If cognitive assessment never occurs, she never receives the diagnosis that would guide her rehabilitation and treatment.
How Clinician Confidence and Awareness Gaps Prevent Early Detection
Recent research from 2025 identifies a fundamental problem: clinicians in non-specialty settings lack confidence in detecting cognitive impairment and have significant gaps in their awareness of VCI as a distinct diagnosis. The Davos Alzheimer’s Collaborative Early Detection Program found that even when cognitive impairment is present, primary care physicians and general neurologists often do not systematically assess it. Delays in diagnosis are common, with patients and families reporting that they navigated the healthcare system for months or years before receiving a diagnosis. During this time, untreated vascular cognitive impairment can progress, brain damage from ongoing small strokes accumulates, and opportunities for vascular risk factor modification diminish. The knowledge gap extends to clinicians’ understanding of what VCI is and how it presents. Many still conceptualize dementia as primarily Alzheimer’s disease, with vascular dementia as a secondary category.
This framing means that when a patient presents with cognitive complaints and vascular risk factors, the clinician may screen for Alzheimer’s (looking for memory impairment) and, finding relatively preserved memory, conclude there’s no dementia. The possibility that executive dysfunction or slowed processing from vascular disease might constitute the cognitive problem simply doesn’t enter the diagnostic thinking. Families report similar confusion, often assuming that cognitive problems after a stroke are temporary effects of the acute event rather than permanent vascular injury to brain tissue. Lack of systematic protocols contributes significantly to this detection failure. In specialty memory clinics, patients receive formal cognitive testing, neuroimaging review, and biomarker assessment. In primary care, which sees most patients with cognitive concerns, appointments average 15 minutes and cognitive assessment typically consists of brief screening questions that may not detect VCI-pattern impairment. A patient who performs normally on the Montreal Cognitive Assessment (which emphasizes memory) but would fail on tests of executive speed and processing may be reassured that “everything looks normal.” The clinician documents “cognitive complaints, dementia workup unremarkable” and the patient returns home with no diagnosis and no treatment plan.
The Overlap Problem—How Mixed Pathology Complicates Every Case
At the cellular level, vascular and Alzheimer’s pathologies intersect in ways that make them difficult to distinguish during life. Vascular damage can promote amyloid accumulation, which in turn impairs blood vessel function—creating a vicious cycle where one pathology worsens the other. Brain imaging may show strokes, white matter disease, and evidence of amyloid accumulation simultaneously, but imaging alone cannot predict which pathology contributes most to the person’s cognitive symptoms. A 68-year-old woman with two small lacunar strokes and mild amyloid positivity on PET imaging might have cognitive impairment driven primarily by the strokes, primarily by amyloid accumulation, or by the combination—and no imaging test can reliably answer which. This uncertainty has practical consequences for treatment decisions.
If her cognitive impairment is primarily vascular, blood pressure control and antiplatelet therapy are central to slowing decline. If it’s primarily Alzheimer’s-related, those interventions matter less, and treatments targeting amyloid or tau accumulation become relevant. If both pathologies contribute equally, she needs aggressive management of both vascular and amyloid risk factors. Yet clinicians must often choose a treatment emphasis without certainty about the underlying cause. Many solve this problem by defaulting to Alzheimer’s-focused care, simply because that diagnostic category is more familiar and has more established treatment algorithms, leaving VCI undertreated even when it’s the primary driver of cognitive decline.
Emerging Detection Methods—What’s Beginning to Close the Recognition Gap
Blood biomarkers are now recognized as a tool for improving VCI detection when integrated with neuroimaging and cognitive assessment. Research in 2025 demonstrates that phosphorylated tau, amyloid-beta, and other markers in blood can help identify the pathological basis of cognitive impairment and distinguish vascular from Alzheimer’s-related contributions. However, biomarker testing remains primarily available in specialty settings and research centers, not in primary care offices where most patients with cognitive concerns initially present. A patient with cognitive impairment whose primary care physician lacks access to blood biomarker testing or knowledge of how to order and interpret these tests will not receive the diagnostic clarity that biomarkers could provide.
Digital cognitive assessment tools represent another emerging solution to the detection gap. The Davos Early Detection Program implemented digital screening in primary care and non-specialty settings, recognizing that paper-and-pencil cognitive testing or verbal screening questions miss many cases of mild cognitive impairment. The Vascular Cognitive Assessment Tool (VCAT), validated in 2025 clinical research, demonstrates strong utility as a practical screening instrument with clear cutoff points that clinicians can use to identify probable VCI. Digital administration of such tools makes cognitive screening feasible in busy primary care settings and creates standardized documentation that supports specialist referral. Yet implementation remains uneven, with adoption dependent on institutional commitment and clinician education rather than widespread system change.
- —
